EyePoint says Phase 3 LUGANO trial of DURAVYU in wet AMD misses primary endpoint

• EyePoint reported topline results from LUGANO, a pivotal Phase 3 trial of DURAVYU for wet age-related macular degeneration.
• The study missed its primary vision endpoint in the full dataset, weighed down by a small cohort with vision loss unrelated to wet AMD.
• An additional analysis excluding that cohort supported comparable vision outcomes versus aflibercept, with lower treatment burden and durable disease control.
• Management pointed to a favorable safety profile with repeat dosing, supporting plans to advance the program toward registration.
• Topline results from the second pivotal Phase 3 trial, LUCIA, are expected in Q4 2026; an FDA filing is planned for 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170700PRIMZONEFULLFEED9811033) on August 17, 2026, and is solely responsible for the information contained therein.